Your sense of self is a carefully constructed illusion, a story you've been telling yourself since you could speak. But what if that narrative could be temporarily dismantled? Psychedelics are doing just that, offering a window into the architecture of our own minds. This disruption might be the key to unlocking deeper levels of therapy.
How does the brain map our sense of self, and what happens when it quiets down?
To understand why psychedelics might be therapeutic, we first need to talk about the Default Mode Network, or DMN. Think of the DMN as the brain's internal storyteller. When you're not actively focusing on something external - like reading this article or watching a movie - the DMN kicks in. It's responsible for self-referential thought: thinking about your past, predicting your future, and generally keeping your personal narrative running smoothly. It's incredibly useful for remembering birthdays or planning next week's grocery list, but sometimes, it can get stuck in negative loops, fueling rumination and anxiety.
Neuroscience has shown that the DMN is deeply interconnected with other systems, particularly the Theory of Mind network. The Theory of Mind network is essentially our ability to understand that other people have their own separate thoughts and feelings that are different from our own. Soares et al. (2023) (strong evidence: meta-analysis) explored the relationship between these two systems, finding that they are intricately linked. When this connection is unbalanced, it can contribute to difficulties in social understanding or maintaining a stable sense of self. The DMN isn't just about you; it's about how you relate to the perceived world and others.
When we talk about psychedelics, we are talking about substances that appear to temporarily dampen the activity within this very network. This isn't necessarily a "shutting off" in a bad way; rather, it's a temporary loosening of the rigid connections that keep our self-narrative so tightly bound. One fascinating area of research looks at the thalamus, a critical relay station deep in the brain. Qiao et al. (2023) (strong evidence: meta-analysis) used resting state functional magnetic resonance imaging (fMRI) to observe that psychedelics can cause pervasive hyperactivity in the thalamus and the DMN. This hyperactivity suggests a kind of 'reboot' or increased communication across different brain regions that are usually kept in check. It's like opening up a complex, dusty filing cabinet that hasn't been opened in years.
This temporary decoupling from the usual self-narrative is what researchers are calling "ego dissolution." It's not about losing your identity; it's about gaining perspective on it. If the DMN is constantly feeding you old worries - "I am inadequate," or "I will fail" - a temporary dip in its activity allows other, perhaps healthier, parts of the brain to come online. This mechanism has been explored both phenomenologically and neurophysiologically. Millière (2017) discussed this in depth, noting that the search for the self involves both philosophical understanding and measurable brain activity. The experience itself is described as a profound sense of interconnectedness, moving beyond the boundaries of the individual ego.
This concept of loosening the self-boundaries is particularly relevant in conditions involving chronic stress or trauma. For instance, in the context of Post-Traumatic Stress Disorder (PTSD), the self often becomes fused with the traumatic event. Maeder et al. (2025) (strong evidence: meta-analysis) conducted a systematic review suggesting that therapeutic paths for PTSD might involve addressing these rigid self-narratives. The goal isn't just symptom reduction; it's restructuring the self's relationship with past trauma. The psychedelic experience, by temporarily disrupting the DMN's grip on the past, might create the necessary psychological space for this restructuring to occur.
Furthermore, the DMN's role in pathology is not always benign. (strong evidence: meta-analysis) provided a systematic review focusing on the subcortical DMN and Alzheimer's Disease. Their work highlights that disruptions in this network are hallmarks of cognitive decline. This suggests that the DMN is a highly sensitive barometer of overall brain health. If psychedelics can modulate this network in a way that appears healthy or restorative, it points toward a fundamental mechanism of plasticity - the brain's ability to rewire itself.
In essence, the therapeutic hypothesis is elegant: if suffering often comes from being too tightly attached to a flawed or painful self-story, then temporarily loosening that attachment - through psychedelics - allows the brain to access a more flexible, integrated, and potentially healthier operating system. It's a forced, yet guided, moment of cognitive spaciousness.
What does the literature say about the DMN and brain function in illness?
The literature strongly points to the DMN being a central hub whose dysregulation is implicated across numerous mental health conditions. The research isn't just observing correlation; it's starting to map functional relationships. For example, the connection between the DMN and the Theory of Mind network, as detailed by Soares et al. (2023) (strong evidence: meta-analysis), suggests that difficulties in understanding others might stem from an over-reliance on an internally focused, rigid self-model. If the DMN is too dominant, we might interpret neutral social cues through the lens of our own anxieties or unmet needs.
The findings from Qiao et al. (2023) (strong evidence: meta-analysis) regarding thalamic hyperactivity are particularly interesting because the thalamus acts as a major gatekeeper for sensory and emotional information. When the DMN is active, it can sometimes create a feedback loop that over-interprets internal signals. The observed hyperactivity suggests that psychedelics might be increasing the brain's overall signal-to-noise ratio, allowing for clearer, less self-filtered processing of reality. This is a key concept in psychedelic-assisted therapy - it's not about hallucinating; it's about enhancing signal clarity.
When we look at neurodegenerative conditions, the DMN's role becomes clearer. (strong evidence: meta-analysis) reviewing the DMN in Alzheimer's Disease showed that the network's integrity is compromised. This reinforces the idea that the DMN is a system that requires constant maintenance and that its breakdown reflects broader cognitive decline. This provides a model: if the network can be modulated positively in a healthy context (like a psychedelic experience), it suggests a potential pathway for intervention.
Moreover, the therapeutic potential is being mapped onto trauma. Maeder et al. (2025) (strong evidence: meta-analysis) review the need to address the self-narrative in PTSD. Trauma often forces the self into a state of hypervigilance, keeping the DMN locked onto threat detection. The psychedelic effect, by inducing a state of 'self unbound' (Letheby & Gerrans, 2017), seems to offer a window where the individual can process memories and emotions without the immediate, overwhelming grip of the survival self. This temporary suspension of the ego's guardrails is what allows for the difficult, but necessary, work of integration.
In summary, the current body of work paints a picture where the DMN is a powerful, necessary, but sometimes overly restrictive operating system for the human mind. Psychedelics appear to be sophisticated, temporary software updates that allow the underlying hardware - the brain - to recalibrate its sense of self and its relationship with reality.
Practical Application: Designing a Psychedelic-Assisted Protocol
Translating the theoretical understanding of the Default Mode Network (DMN) and ego dissolution into a safe, therapeutic protocol requires careful, phased implementation. The goal is not simply to induce a psychedelic state, but to guide the patient through a structured experience that maximizes neuroplastic change while minimizing acute distress. A potential protocol, requiring supervision by trained clinicians, could involve a combination of set and setting management, controlled dosing, and integration work.
Phase 1: Preparation and Psychoeducation (Weeks 1-3)
This initial phase focuses heavily on building rapport and psychoeducation. The patient must understand the concept of the DMN - that its overactivity can contribute to rumination, self-referential bias, and anxiety. They need to understand that the psychedelic experience is a temporary, drug-mediated shift, not a permanent alteration of self. Weekly sessions (60 minutes) are recommended, focusing on mindfulness techniques to ground the patient in their baseline state and identifying personal "narrative traps" within their DMN activity. Homework involves journaling about moments of self-criticism or excessive rumination.
Phase 2: The Acute Experience (Day 1)
The actual dosing session should occur in a highly controlled, comfortable, and non-clinical setting (the "setting"). A low-to-moderate dose of a compound like psilocybin or LSD is often preferred for initial protocols. The session duration should be approximately 6-8 hours, with the patient monitored continuously. The timing is crucial: the session begins after the patient has completed the preparatory work. During the peak of the experience, the therapist's role shifts from active guidance to co-regulation - providing a stable, non-judgmental presence. The focus is on allowing the dissolution of rigid self-boundaries, observing the internal chaos without reacting to it, and anchoring to sensory input (e.g., music, physical touch) when anxiety spikes. This controlled exposure allows the DMN to temporarily downregulate its excessive connectivity.
Phase 3: Integration and Consolidation (Weeks 2-6)
This is arguably the most critical phase. The immediate aftermath of the drug experience is volatile; the insights must be metabolized into lasting behavioral change. Weekly sessions (75 minutes) are scheduled for the first month post-dosing. These sessions are dedicated to "mapping" the experience. Clinicians guide the patient to articulate what they observed during ego dissolution - what beliefs felt fluid, what narratives seemed fragile, and what emotions were experienced without the usual cognitive filter. Techniques like narrative restructuring and embodiment exercises are used to help the patient build new, less rigid self-models that can be practiced in daily life, thereby retraining the DMN toward more flexible connectivity.
What Remains Uncertain
Despite the promising preclinical and early clinical data, the field remains fraught with unknowns. The primary limitation is the lack of standardized, universally accepted dosing protocols. What constitutes an optimal dose, frequency, or duration varies wildly depending on the specific condition being treated (e.g., treatment-resistant depression versus anxiety). Furthermore, the "optimal" therapeutic window remains undefined; too little intervention may fail to disrupt entrenched DMN patterns, while too much intervention risks overwhelming the patient's capacity for integration, leading to acute psychological distress or retraumatization.
Another significant unknown is the mechanism of long-term change. While we observe behavioral improvements post-treatment, the precise neurobiological correlates - the measurable, sustained downregulation of specific DMN nodes - are not consistently tracked across all studies. Moreover, the influence of co-occurring conditions, such as complex trauma or substance use disorders, introduces variables that current protocols are ill-equipped to manage safely. Future research must prioritize longitudinal, multimodal studies that combine advanced neuroimaging (to track DMN connectivity changes) with rigorous, standardized psychotherapy measures. Until such thorough guidelines are established, the use of psychedelics must remain highly restricted to supervised, research-adjacent settings.
Core claims are supported by peer-reviewed research including systematic reviews.
References
- Soares C, Gonzalo G, Castelhano J (2023). The relationship between the default mode network and the theory of mind network as revealed by psyc. Neuroscience & Biobehavioral Reviews. DOI
- Qiao Y, Fu C, Zhao N (2023). Resting state fMRI reveals pervasive thalamic hyperactivity and default mode network hypoactivity in. . DOI
- Seoane S, van den Heuvel M, Acebes Á (2023). The Subcortical Default Mode Network and Alzheimer's Disease: A systematic review and Activation Lik. . DOI
- Maeder S, Fahim C, Martin-Soelch C (2025). Towards therapeutic paths in Post-Traumatic Stress Disorder: Systematic review and meta-analysis of . . DOI
- . Self unbound: ego dissolution in psychedelic experience. Neuroscience of Consciousness. DOI
- . Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced . Frontiers in Human Neuroscience. DOI
- Stoliker D, Egan G, Razi A (2021). Reduced precision underwrites ego dissolution and therapeutic outcomes under psychedelics. . DOI
- Robin Carhart‐Harris, Karl Friston (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews. DOI
- . Psychedelics, Meditation, and Self-Consciousness. Frontiers in Psychology. DOI
- Nour M, Evans L, Nutt D (2016). Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience. DOI